ImmunityBio Inc (NASDAQ:IBRX) has a beta value of 0.39 and has seen 1.69 million shares traded in the recent trading session. The company, currently valued at $2.61B, closed the recent trade at $3.06 per share which meant it lost -$0.08 on the day or -2.71% during that session. The IBRX stock price is -244.12% off its 52-week high price of $10.53 and 25.49% above the 52-week low of $2.28. If we look at the company’s 10-day average daily trading volume, we find that it stood at 6.25 million shares traded. The 3-month trading volume is 6.16 million shares.
The consensus among analysts is that ImmunityBio Inc (IBRX) is Sell stock at the moment, with a recommendation rating of 1.40. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 0 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.14.
ImmunityBio Inc (NASDAQ:IBRX) trade information
Sporting -2.71% in the red today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the IBRX stock price touched $3.06 or saw a rise of 11.82%. Year-to-date, ImmunityBio Inc shares have moved 19.34%, while the 5-day performance has seen it change 7.19%. Over the past 30 days, the shares of ImmunityBio Inc (NASDAQ:IBRX) have changed -7.14%. Short interest in the company has seen 59.54 million shares shorted with days to cover at 9.03.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 49.0% from the levels at last check today.. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the latest price level in today’s session is -96.08% off the targeted high while a plunge would see the stock gain -96.08% from the levels at last check today..
ImmunityBio Inc (IBRX) estimates and forecasts
The company’s shares have lost -21.67% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 613.74%.
4 analysts offering their estimates for the company have set an average revenue estimate of 17.5M for the current quarter. 4 have an estimated revenue figure of 23.5M for the next ending quarter. Year-ago sales stood 40k and 1.05M respectively for this quarter and the next, and analysts expect sales will grow by 43,644.38% for the current quarter and 613.74% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 2.39% over the past 5 years.
IBRX Dividends
ImmunityBio Inc is expected to release its next earnings report on 2025-Mar-02 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ImmunityBio Inc (NASDAQ:IBRX)’s Major holders
Insiders own 62.90% of the company shares, while shares held by institutions stand at 9.88% with a share float percentage of 26.63%. Investors are also buoyed by the number of investors in a company, with ImmunityBio Inc having a total of 273.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 13.83 million shares worth more than $87.42 million. As of 2024-06-30, VANGUARD GROUP INC held 2.0558% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 11.42 million shares as of 2024-06-30. The firm’s total holdings are worth over $72.19 million and represent 1.6629% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of Feb 28, 2025 , the former fund manager holds about 0.68% shares in the company for having 5.84 shares of worth $17.75 million while later fund manager owns 5.73 shares of worth $17.43 million as of Dec 31, 2024 , which makes it owner of about 0.67% of company’s outstanding stock.
